↓ Skip to main content

Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease

Overview of attention for article published in Alzheimer's Research & Therapy, October 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)

Mentioned by

1 news outlet
2 X users
1 patent


123 Dimensions

Readers on

151 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
Published in
Alzheimer's Research & Therapy, October 2009
DOI 10.1186/alzrt6
Pubmed ID

Roy O Weller, Stephen D Preston, Malavika Subash, Roxana O Carare


Amyloid is deposited in the walls of arteries and capillaries as cerebral amyloid angiopathy (CAA) in the brains of older individuals and of those with Alzheimer disease (AD). CAA in AD reflects an age-related failure of elimination of amyloid-beta (Abeta) from the brain along perivascular lymphatic drainage pathways. In the absence of conventional lymphatic vessel in the brain, interstitial fluid and solutes drain from the brain to cervical lymph nodes along narrow basement membranes in the walls of capillaries and arteries, a pathway that is largely separate from the cerebrospinal fluid. In this review we focus on the pathology and pathogenesis of CAA, its role in the aetiology of AD and its impact on immunotherapy for AD. The motive force for lymphatic drainage of the brain appears to be generated by arterial pulsations. Failure of elimination of Abeta along perivascular pathways coincides with a reduction in enzymic degradation of Abeta, reduced absorption of Abeta into the blood and age-related stiffening of artery walls that appears to reduce the motive force for lymphatic drainage. Reduced clearances of Abeta and CAA are associated with the accumulation of insoluble and soluble Abetas in the brain in AD and the probable loss of homeostasis of the neuronal environment due to retention of soluble metabolites within the brain. Tau metabolism may also be affected. Immunotherapy has been successful in removing insoluble plaques of Abeta from the brain in AD but with little effect on cognitive decline. One major problem is the increase in CAA in immunised patients that probably prevents the complete removal of Abeta from the brain. Increased knowledge of the physiology and structural and genetic aspects of the lymphatic drainage of Abeta from the brain will stimulate the development of therapeutic strategies for the prevention and treatment of AD.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 151 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 2%
United States 2 1%
Korea, Republic of 2 1%
South Africa 1 <1%
India 1 <1%
Netherlands 1 <1%
Japan 1 <1%
Spain 1 <1%
Unknown 139 92%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 32 21%
Researcher 21 14%
Student > Master 17 11%
Student > Bachelor 14 9%
Student > Doctoral Student 11 7%
Other 39 26%
Unknown 17 11%
Readers by discipline Count As %
Medicine and Dentistry 44 29%
Agricultural and Biological Sciences 35 23%
Neuroscience 24 16%
Biochemistry, Genetics and Molecular Biology 9 6%
Engineering 5 3%
Other 13 9%
Unknown 21 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2023.
All research outputs
of 25,374,647 outputs
Outputs from Alzheimer's Research & Therapy
of 1,465 outputs
Outputs of similar age
of 105,837 outputs
Outputs of similar age from Alzheimer's Research & Therapy
of 3 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,465 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 105,837 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them